After years of searching, we have finally found it – a new, common genetic cause of #congenitalhyperinsulinism Until now these disease-causing variants have remained frustrating elusive, they had been hiding deep in the non-coding genome University of Exeter Faculty of Health & Life Sci University of Exeter ExeterDiabetes

History is made fda.gov/news-events/pr…

Tepluzimab, an anti-CD3 antibody, which has been shown to slow the onset of type 1 diabetes has now been approved by the FDA for children and adults with preclinical type 1 diabetes. It is not currently licensed in the UK and will need to be approved before it becomes available.

This is a historic breakthrough towards eradicating type 1 diabetes. Proud to be Ambassador for JDRF UK whose funding & research over three decades has been instrumental in the development of this game-changing therapy.

Amazing opportunity for a paediatric diabetes nurse or paediatric research nurse to join University of Oxford diabetes research team! Paving the way in #T1D prevention and improved #diabetes care. Details here: my.corehr.com/pls/uoxrecruit…

Great to be in Munich with new and old friends, creating a vision for T1D screening, and co leading WP3 of EDENT1FI on follow up T1Early Laura Baum

Happy to be in Munich for the kick off meeting of EDENT1FI with strong UK representation! We're talking #T1D screening today and tomorrow

One in six billion podcast 𝐄𝐩𝐢𝐬𝐨𝐝𝐞 𝐭𝐰𝐨: 𝐀𝐧𝐧𝐚 𝐆𝐥𝐨𝐲𝐧 - 𝐭𝐡𝐞 𝐠𝐞𝐧𝐞 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐯𝐞 available now! The story of neonatal diabetes continues as we hear about Anna Gloyn and her remarkable science that led to gene identification in neonatal diabetes.

So happy to see our paper published in Diabetes Care, a research journal of the ADA 🌟 thanks to all participants and co-authors! Type 1 #diabetes #T1D Check out the paper here doi.org/10.2337/dc23-1… John Andrew Todd Anna Gloyn T1Early

2023 was a big year for research 🧑🏽‍🔬 We invested over £20 million of generous donations into cutting-edge diabetes research 🙌🏼 Take a closer look at some of the research heading up 2024 👉🏼 orlo.uk/vkQ8J PS. We couldn’t do it without you! 💙

The future of #Medicine ? There is a LOT to be excited about, including for #T1diabetes Come and hear about it all in the New Scientist Events T1Early newscientist.com/science-events….

#Exercise is an effective treatment for depression, with walking or jogging, yoga, and strength training more effective than other exercises, particularly when intense, finds this new study. Includes a visual abstract summarising key findings Michael Noetel🔸 bmj.com/content/384/bm…

📢New publication! This is the 1st paper from Turning the T1DE's thesis and is reviewing stigma in #T1D & the effect it has on #Diabetes management. Key findings 1. Stigma is global🌍 2. It has a universally negative effect on diabetes management🙁 (1/4) onlinelibrary.wiley.com/doi/10.1111/dm…

Thanks to Diabetes UK Research, this collaborative effort will help change the narrative of #T1diabetes bringing together all UK screening platforms, thanks for support from Partha S Kar 🇮🇳🇬🇧🏏🎥 Fulya Mehta

On May 18th the New Scientist Events will become a platform to hear all about #type1diabetes #screening and intervention, hope to see you there! The future of #medicine? The audience will decide....New Scientist Fulya Mehta Partha S Kar 🇮🇳🇬🇧🏏🎥 @clarehambling Richard Oram newscientist.com/science-events…

Huge congrats to Anastasia at Breakthrough T1D for masterminding this consensus, and Moshe and Linda for their leadership. Proud to co chair the paediatric working group. pubmed.ncbi.nlm.nih.gov/38912694/ #T1Diabetes # screening

How can you monitor a child, young person or adult with positive antibodies in clinical practice? Here's how ....pubmed.ncbi.nlm.nih.gov/38912694/ Rachel Besser #T1diabetes

A general population screening strategy for #T1D? Aligning with a vaccination visit looks feasible and acceptable in this proof of concept study T1Early National Institute for Health and Care Research NIHR Oxford Biomedical Research Centre @besser adc.bmj.com/content/early/…

#Screening for #T1D is nothing without its follow-up programme, but when is the right rime to start #insulin in an individual gradually evolving to stage 3 T1d? Here are some thoughts The Lancet Diabetes & Endocrinology Rachel Besser Fulya Mehta Parth thelancet.com/journals/landi…